Highlights
- Second quarter revenue of $665.1 million increased by 8% as
reported with non-respiratory revenue up 3% on a supplemental
combined basis (up 4% in constant currency) and respiratory revenue
down 74% on a supplemental combined basis
- Non-respiratory revenue driven by 9% constant currency growth
in Labs business unit
- Second quarter GAAP loss per share of $(0.80); adjusted EPS of
$0.26, an 88% decrease from prior year on a supplemental combined
basis, largely reflecting the strength of respiratory revenue in
the second quarter of 2022
- Paid down $72 million on Term Loan ($20 million more than
contractually required) and completed the final $40 million payment
for the 2017 acquisition of the Alere Cardiometabolic assets
- Completed the Savanna® Emergency Use Authorization (“EUA”) and
510(k) FDA submissions as planned
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or
“QuidelOrtho”), a global provider of innovative in vitro diagnostic
technologies designed for point-of-care settings, clinical labs and
transfusion medicine, today announced financial results for the
second quarter ended July 2, 2023.
The Company reported total revenue for the second quarter of
2023 of $665.1 million, compared to $613.4 million for the second
quarter of 2022. GAAP diluted loss per share (LPS) for the second
quarter of 2023 decreased to $(0.80), compared to diluted EPS of
$0.36 for the second quarter of 2022. GAAP operating loss for the
second quarter of 2023 was $(26.9) million, compared to operating
income of $79.7 million for the second quarter of 2022, and GAAP
operating margin was (4)% and 13% for the second quarters of 2023
and 2022, respectively. The second quarter 2023 results include
significant one-time charges related to the integration.
In addition to the Company’s GAAP results, the Company is
providing supplemental combined second quarter 2022 revenues and
adjusted operating results as if Quidel Corporation (“Quidel”) and
Ortho Clinical Diagnostics Holdings plc (“Ortho”) had been combined
for the applicable periods. The following discussion of financial
results is based on supplemental combined information:
Second quarter 2023 total revenue of $665.1 million decreased by
26% in constant currency, compared to $898.5 million for the second
quarter of 2022. Foreign currency translation negatively impacted
sales growth by approximately 10 basis points for the second
quarter of 2023. Adjusted diluted EPS for the second quarter of
2023 decreased to $0.26, compared to $2.12 for the second quarter
of 2022. Adjusted EBITDA for the second quarter of 2023 was $113.3
million, compared to $290.8 million in the second quarter of 2022.
Adjusted EBITDA margin for the second quarter of 2023 was 17.0%,
compared to 32.4% for the second quarter of 2022.
“We are pleased with our solid financial results in the second
quarter largely driven by continued strength in our Labs business
across all major geographic regions. Equally important, our
execution on our key growth drivers was outstanding in the quarter
– our Labs backlog is approaching normalized levels and utilization
is increasing, Sofia® non-COVID pull-through continues to increase,
and Savanna EUA and 510(k) submissions were completed as planned,”
said Douglas Bryant, President and Chief Executive Officer of
QuidelOrtho. “Looking to the future, we will continue to identify
additional cost synergies and the integration is now in its final
phase, which will focus on our future growth model by identifying,
prioritizing and executing transformational initiatives that will
accelerate our growth, foster productivity and enable us to be a
more nimble, responsive organization.”
Fiscal Year 2023 Financial Guidance
The Company will provide 2023 financial guidance during its
financial results conference call today.
Conference Call Information
QuidelOrtho will hold a conference call today at 2:00 p.m. PT /
5:00 p.m. ET to discuss its financial results for the second
quarter ended July 2, 2023. Interested parties can access the call
on the “Events & Presentations” section of the “Investor
Relations” page of the Company’s website at
https://ir.quidelortho.com/. Presentation materials will also be
posted to the “Events & Presentations” section of the “Investor
Relations” page of the Company’s website at the time of the call.
Those unable to access the webcast may join the call via phone by
dialing 833-470-1428 (domestic) or 929-526-1599 (international) and
entering Conference ID number 695066.
A replay of the conference call will be available shortly after
the event on the “Investor Relations” page of the Company’s
website, under the “Events & Presentations” section.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in
vitro diagnostics, developing and manufacturing intelligent
solutions that transform data into understanding and action for
more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular
testing, clinical chemistry and transfusion medicine, bringing
fast, accurate and reliable diagnostics when and where they are
needed – from home to hospital, lab to clinic. So that patients,
clinicians and health officials can spot trends sooner, respond
quicker and chart the course ahead with accuracy and
confidence.
Building upon its 80-year legacy of groundbreaking innovation,
QuidelOrtho continues to partner with customers across the
healthcare continuum and around the globe to forge a new diagnostic
frontier. One where insights and solutions know no bounds,
expertise seamlessly connects and a more informed path is
illuminated for each of us.
QuidelOrtho is transforming the power of diagnostics into a
healthier future for all.
For more information, please visit www.quidelortho.com.
Source: QuidelOrtho Corporation
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements include any statements contained herein that
are not strictly historical, including, but not limited to, the
synergies and other benefits and results of the business
combination of Quidel and Ortho (the “Combinations”) and
integration of the businesses of Quidel and Ortho, and
QuidelOrtho’s commercial, integration, transformation and other
strategic goals, future financial and operating results, and future
plans, objectives, strategies, expectations and intentions. These
statements in this press release may be identified by words such as
“may,” “will,” “would,” “should,” “might,” “expect,” “anticipate,”
“believe,” “estimate,” “plan,” “intend,” “goal,” “project,”
“strategy,” “future,” “continue” or similar words, expressions or
the negative of such terms or other comparable terminology. Such
statements are based on the beliefs and expectations of
QuidelOrtho’s management as of today and are subject to significant
known and unknown risks and uncertainties. Actual results or
outcomes may differ significantly from those set forth or implied
in the forward-looking statements. The following factors, among
others, could cause actual results to differ from those set forth
or implied in the forward-looking statements: the challenges and
costs of integrating, restructuring and achieving anticipated
synergies as a result of the Combinations; the ability to retain
key employees; and other economic, business, competitive and/or
regulatory factors affecting the business of QuidelOrtho generally.
Additional risks and factors are identified under “Risk Factors” in
QuidelOrtho’s Annual Report on Form 10-K filed with the Securities
and Exchange Commission (the “Commission”) on February 23, 2023 and
subsequent reports filed with the Commission. You should not rely
on forward-looking statements as predictions of future events
because these statements are based on assumptions that may not come
true and are speculative by their nature. QuidelOrtho undertakes no
obligation to update any of the forward-looking information or
time-sensitive information included in this press release, whether
as a result of new information, future events, changed expectations
or otherwise, except as required by law. All forward-looking
statements are based on information currently available to
QuidelOrtho and speak only as of the date hereof.
Supplemental Combined Financial Measures
This press release contains unaudited supplemental combined
financial information (“Supplemental Combined Information”) that
gives effect to the Combinations as if Quidel and Ortho had been
combined for the applicable periods. Certain Supplemental Combined
Information presented is based on the historical financial
statements of Quidel and Ortho with reclassification adjustments
only and do not include all of the pro forma adjustments required
under Regulation S-X Article 11 or Accounting Standards
Codification 805, Business Combinations (“ASC 805”). The
Supplemental Combined Information is provided for illustrative
purposes only, may be updated in the future, and is not
necessarily, and should not be assumed to be, indicative of the
Company’s expected results of operations or financial position that
would have been achieved had the Combinations been completed as of
the dates indicated or that may be achieved in any future period.
The Supplemental Combined Information should be considered
supplemental to, and not as a substitute for, pro forma financial
information prepared in accordance with Regulation S-X Article 11
or ASC 805 and should be read in conjunction with the information
contained in the sections entitled “The Combinations,”
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations of Ortho” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations of
Quidel” in QuidelOrtho’s joint proxy statement/prospectus (the
“Joint Proxy Statement/Prospectus”) filed with the Commission on
April 11, 2022 and the historical consolidated financial statements
and related notes appearing elsewhere in, or incorporated into, the
Joint Proxy Statement/Prospectus, and the Company’s subsequent
reports filed with the Commission. The Company’s actual results of
operations and financial position will differ, potentially
significantly, from the Supplemental Combined Information reflected
in this press release as a result of the methodology used to
prepare the Supplemental Combined Information as well as a variety
of factors, including but not limited to the effect of certain
expected financial benefits of the Combinations (such as revenue
and cost synergies), the anticipated costs to achieve these
benefits (including the cost of integration activities), tax
impacts, and changes in operating results following the date of
this press release.
Non-GAAP Financial Measures
This press release contains financial measures, including but
not limited to “constant currency” revenue changes, “adjusted net
income,” “adjusted diluted EPS,” “adjusted EBITDA,” “adjusted
EBITDA margin,” “supplemental combined adjusted net income,”
“supplemental combined adjusted diluted EPS,” “supplemental
combined adjusted EBITDA” and “supplemental combined adjusted
EBITDA margin,” which are considered non-GAAP financial measures
under applicable rules and regulations of the Commission. These
non-GAAP financial measures should be considered supplemental to,
and not a substitute for, financial information prepared in
accordance with U.S. generally accepted accounting principles
(“GAAP”). “Adjusted net income,” “adjusted EBITDA” and “adjusted
diluted EPS” eliminate impacts of certain non-cash, unusual or
other items that the Company does not consider indicative of its
ongoing operating performance, and the Company generally uses these
non-GAAP financial measures to facilitate management’s financial
and operational decision-making, including evaluation of the
Company’s historical operating results and comparison to
competitors’ operating results. The Company believes that
“supplemental combined adjusted net income,” “supplemental combined
adjusted diluted EPS,” “supplemental combined adjusted EBITDA” and
“supplemental combined adjusted EBITDA margin” provide helpful
Supplemental Combined Information to assist management and
investors in evaluating the Company’s adjusted operating results as
if Quidel and Ortho had been combined for the applicable periods.
The Company’s definitions of these non-GAAP measures may differ
from similarly titled measures used by others. These non-GAAP
financial measures reflect an additional way of viewing aspects of
the Company’s operations that, when viewed with GAAP results and
the reconciliations to corresponding GAAP financial measures, may
provide a more complete understanding of factors and trends
affecting the Company’s business. Because non-GAAP financial
measures exclude the effect of items that will increase or decrease
the Company’s reported results of operations, management strongly
encourages investors to review the Company’s consolidated financial
statements and reports filed with the Commission in their entirety.
Reconciliations of the non-GAAP financial measures, including the
non-GAAP Supplemental Combined Information, to the most directly
comparable GAAP financial measures are included in the tables
accompanying this press release.
QuidelOrtho
Consolidated Statements of
Operations
(Unaudited)
(In millions except per share
data)
Three Months Ended
Six Months Ended
July 2, 2023 (a)
July 3, 2022 (b)
July 2, 2023 (a)
July 3, 2022 (b)
Total revenues
$
665.1
$
613.4
$
1,511.2
$
1,615.7
Cost of sales, excluding amortization of
intangibles
368.7
275.9
766.2
536.2
Selling, marketing and administrative
179.1
118.4
381.5
203.2
Research and development
62.8
34.2
125.1
60.6
Amortization of intangible assets
51.4
21.0
102.2
28.1
Acquisition and integration costs
24.2
80.2
53.9
83.2
Other operating expenses
5.8
4.0
9.6
4.0
Operating (loss) income
(26.9
)
79.7
72.7
700.4
Interest expense, net
36.5
10.3
73.2
11.3
Loss on extinguishment of debt
—
24.0
—
24.0
Other expense, net
1.0
2.5
3.9
1.6
(Loss) income before income taxes
(64.4
)
42.9
(4.4
)
663.5
(Benefit from) provision for income
taxes
(11.2
)
23.6
—
164.3
Net (loss) income
$
(53.2
)
$
19.3
$
(4.4
)
$
499.2
Basic (loss) earnings per share
$
(0.80
)
$
0.37
$
(0.07
)
$
10.62
Diluted (loss) earnings per share
$
(0.80
)
$
0.36
$
(0.07
)
$
10.47
Weighted-average shares outstanding -
basic
66.8
52.2
66.7
47.0
Weighted-average shares outstanding -
diluted
66.8
52.9
66.7
47.7
(a)
Includes Ortho results of operations for
the three and six months ended July 2, 2023.
(b)
Includes Ortho results of operations from
May 27, 2022 through July 3, 2022.
QuidelOrtho
Condensed Consolidated Balance
Sheets
(Unaudited)
(In millions)
July 2, 2023
January 1, 2023
Cash and cash equivalents
$
178.6
$
292.9
Marketable securities
45.1
52.1
Accounts receivable, net
246.7
453.9
Inventories
542.2
524.1
Prepaid expenses and other current
assets
295.5
252.1
Property, plant and equipment, net
1,376.2
1,339.0
Marketable securities
24.7
21.0
Right-of-use assets
177.4
181.0
Goodwill
2,470.9
2,476.8
Intangible assets, net
3,035.7
3,123.8
Deferred tax asset
16.1
16.4
Other assets
141.2
122.7
Total assets
$
8,550.3
$
8,855.8
Accounts payable
$
225.9
$
283.3
Accrued payroll and related expenses
81.5
139.2
Income tax payable
2.1
51.6
Current portion of borrowings
207.4
207.5
Other current liabilities
273.1
325.4
Operating lease liabilities
181.2
186.4
Long-term borrowings
2,308.5
2,430.8
Deferred tax liability
199.6
213.2
Other liabilities
68.5
83.8
Total liabilities
3,547.8
3,921.2
Total stockholders’ equity
5,002.5
4,934.6
Total liabilities and stockholders’
equity
$
8,550.3
$
8,855.8
QuidelOrtho
Condensed Consolidated Statements
of Cash Flows
(Unaudited)
(In millions)
Six Months Ended
July 2, 2023 (a)
July 3, 2022 (b)
Cash provided by operating activities
$
158.3
$
725.6
Cash used for investing activities
(111.2
)
(1,555.1
)
Cash (used for) provided by financing
activities
(159.3
)
409.7
Effect of exchange rates on cash
(2.1
)
(2.4
)
Net decrease in cash, cash equivalents and
restricted cash
(114.3
)
(422.2
)
Cash, cash equivalents and restricted cash
at beginning of period
293.9
802.8
Cash, cash equivalents and restricted cash
at end of period
$
179.6
$
380.6
Reconciliation to amounts within the
consolidated balance sheets:
Cash and cash equivalents
$
178.6
$
379.0
Restricted cash in Other assets
1.0
1.6
Cash, cash equivalents and restricted
cash
$
179.6
$
380.6
(a)
Includes Ortho activities for the six
months ended July 2, 2023.
(b)
Includes Ortho activities from May 27,
2022 through July 3, 2022.
QuidelOrtho
Reconciliation of Non-GAAP
Financial Information - Adjusted Net Income
(In millions, except per share
data; unaudited)
Three Months Ended
Six Months Ended
July 2, 2023 (a)
Diluted EPS
July 3, 2022 (b)
Diluted
EPS
July 2, 2023 (a)
Diluted
EPS
July 3, 2022 (b)
Diluted
EPS
Net (loss) income
$
(53.2
)
$
(0.80
)
$
19.3
$
0.36
$
(4.4
)
$
(0.07
)
$
499.2
$
10.47
Adjustments:
Amortization of intangibles
51.4
21.0
102.2
28.1
Acquisition and integration costs
24.2
80.2
53.9
83.2
Incremental depreciation on PP&E fair
value
adjustment
8.5
—
17.1
—
Amortization of deferred cloud
computing
implementation costs
1.5
1.3
3.1
2.3
EU medical device regulation transition
costs
0.7
0.4
1.5
0.4
Impairment of long-lived assets
0.5
—
1.0
—
Loss on investments
0.2
0.8
0.2
0.8
Noncash interest expense for deferred
consideration
0.1
0.8
0.7
1.7
Loss on extinguishment of debt
—
24.0
—
24.0
Unwind inventory fair value adjustment
—
11.2
—
11.2
Employee compensation charges and other
costs
—
0.5
1.5
0.5
Change in fair value of acquisition
contingencies
—
0.1
—
0.1
Derivative mark-to-market gain
—
(1.0
)
—
(1.0
)
Income tax impact of adjustments
(15.2
)
(34.9
)
(37.3
)
(37.5
)
Discrete tax items
(1.3
)
—
(1.1
)
—
Adjusted net income
$
17.4
$
0.26
$
123.7
$
2.34
$
138.4
$
2.06
$
613.0
$
12.85
Ortho pre-combination adjusted net
income
—
20.2
—
77.2
Supplemental combined adjusted net
income
$
17.4
$
0.26
$
143.9
$
2.12
$
138.4
$
2.06
$
690.2
$
10.15
Weighted-average shares outstanding -
diluted
67.2
52.9
67.2
47.7
Weighted-average shares outstanding -
diluted - supplemental combined
67.2
68.0
67.2
68.0
(a)
Adjusted net income includes Ortho
activities for the three and six months ended July 2, 2023.
(b)
Adjusted net income includes Ortho
activities from May 27, 2022 through July 3, 2022.
QuidelOrtho
Reconciliation of Non-GAAP
Financial Information - Adjusted EBITDA
(In millions, unaudited)
Three Months Ended
Six Months Ended
July 2, 2023 (a)
July 3, 2022 (b)
July 2, 2023 (a)
July 3, 2022 (b)
Net (loss) income
$
(53.2
)
$
19.3
$
(4.4
)
$
499.2
Depreciation and amortization
114.5
47.5
228.7
62.8
Interest expense, net
36.5
10.3
73.2
11.3
(Benefit from) provision for income
taxes
(11.2
)
23.6
—
164.3
Acquisition and integration costs
24.2
80.2
53.9
83.2
Amortization of deferred cloud computing
implementation costs
1.5
1.3
3.1
2.3
EU medical device regulation transition
costs
0.7
0.4
1.5
0.4
Impairment of long-lived assets
0.5
—
1.0
—
Loss on investments
0.2
0.8
0.2
0.8
Tax indemnification income
(0.4
)
—
(0.1
)
—
Loss on extinguishment of debt
—
24.0
—
24.0
Unwind inventory fair value adjustment
—
11.2
—
11.2
Employee compensation charges and other
costs
—
0.5
1.5
0.5
Change in fair value of acquisition
contingencies
—
0.1
—
0.1
Derivative mark-to-market gain
—
(1.0
)
—
(1.0
)
Adjusted EBITDA
$
113.3
$
218.2
$
358.6
$
859.1
Ortho pre-combination Adjusted EBITDA
—
72.6
—
212.5
Supplemental combined Adjusted EBITDA
$
113.3
$
290.8
$
358.6
$
1,071.6
(a)
Adjusted EBITDA includes Ortho activities
for the three and six months ended July 2, 2023.
(b)
Adjusted EBITDA includes Ortho activities
from May 27, 2022 through July 3, 2022.
QuidelOrtho
Supplemental Combined Revenues by
Business Unit and Region
(In millions, unaudited)
Three Months Ended
July 2, 2023
July 3, 2022
% Change
Currency
Impact
Constant
Currency (a)
Respiratory revenues
$
89.0
$
339.1
(73.8
)%
—
%
(73.8
)%
Non-Respiratory revenues
576.1
559.4
3.0
%
(1.1
)%
4.1
%
Total supplemental combined revenues
$
665.1
$
898.5
(26.0
)%
(0.1
)%
(25.9
)%
Three Months Ended
July 2, 2023
July 3, 2022
% Change
Currency
Impact
Constant
Currency (a)
Respiratory
Revenue Impact
Constant Currency (a)
Non-Respiratory
Revenue
Labs
$
361.4
$
342.0
5.7
%
(1.3
)%
7.0
%
(2.1
)%
9.1
%
Transfusion Medicine
163.3
168.8
(3.3
)%
(0.8
)%
(2.5
)%
—
%
(2.5
)%
Point of Care
134.2
367.0
(63.4
)%
0.1
%
(63.5
)%
(59.0
)%
(4.5
)%
Molecular Diagnostics
6.2
20.7
(70.0
)%
—
%
(70.0
)%
(62.6
)%
(7.4
)%
Total supplemental combined revenues
$
665.1
$
898.5
(26.0
)%
(0.1
)%
(25.9
)%
(30.0
)%
4.1
%
Three Months Ended
July 2, 2023
July 3, 2022
% Change
Currency
Impact
Constant
Currency (a)
Respiratory
Revenue Impact
Constant Currency (a)
Non-Respiratory
Revenue
North America
$
378.8
$
595.7
(36.4
)%
(0.3
)%
(36.1
)%
(34.4
)%
(1.7
)%
EMEA
80.6
82.9
(2.8
)%
(0.3
)%
(2.5
)%
(6.0
)%
3.5
%
China
81.3
96.1
(15.4
)%
(2.0
)%
(13.4
)%
(38.9
)%
25.5
%
Other
124.4
123.8
0.5
%
(0.6
)%
1.1
%
(7.7
)%
8.8
%
Total supplemental combined revenues
$
665.1
$
898.5
(26.0
)%
(0.1
)%
(25.9
)%
(30.0
)%
4.1
%
Tables above include Ortho revenues as if the acquisition had
occurred on January 2, 2022.
(a)
The term “constant currency” means we have
translated local currency revenues for all reporting periods to
U.S. dollars using currency exchange rates held constant for each
period. This additional non-GAAP financial information is not meant
to be considered in isolation from or as substitute for financial
information prepared in accordance with GAAP.
Six Months Ended
July 2, 2023
July 3, 2022
% Change
Currency
Impact
Constant
Currency (a)
Respiratory revenues
$
354.6
$
1,286.4
(72.4
)%
—
%
(72.4
)%
Non-Respiratory revenues
1,156.6
1,114.5
3.8
%
(1.6
)%
5.4
%
Total supplemental combined revenues
(b)
$
1,511.2
$
2,400.9
(37.1
)%
(0.1
)%
(37.0
)%
Six Months Ended
July 2, 2023
July 3, 2022
% Change
Currency
Impact
Constant
Currency (a)
Respiratory
Revenue Impact
Constant Currency (a)
Non-Respiratory
Revenue
Labs (b)
$
732.1
$
681.7
7.4
%
(1.7
)%
9.1
%
(2.8
)%
11.9
%
Transfusion Medicine
319.2
342.5
(6.8
)%
(1.5
)%
(5.3
)%
—
%
(5.3
)%
Point of Care
442.3
1,310.0
(66.2
)%
—
%
(66.2
)%
(67.3
)%
1.1
%
Molecular Diagnostics
17.6
66.7
(73.6
)%
0.1
%
(73.7
)%
(56.3
)%
(17.4
)%
Total supplemental combined revenues
(b)
$
1,511.2
$
2,400.9
(37.1
)%
(0.1
)%
(37.0
)%
(42.4
)%
5.4
%
Six Months Ended
July 2, 2023
July 3, 2022
% Change
Currency
Impact
Constant
Currency (a)
Respiratory
Revenue Impact
Constant Currency (a)
Non-Respiratory
Revenue
North America
$
961.6
$
1,833.5
(47.6
)%
(0.2
)%
(47.4
)%
(48.8
)%
1.4
%
EMEA
161.9
166.9
(3.0
)%
(1.9
)%
(1.1
)%
(4.6
)%
3.5
%
China
151.9
159.4
(4.7
)%
(4.0
)%
(0.7
)%
(24.0
)%
23.3
%
Other
235.8
241.1
(2.2
)%
(2.0
)%
(0.2
)%
(8.9
)%
8.7
%
Total supplemental combined revenues
(b)
$
1,511.2
$
2,400.9
(37.1
)%
(0.1
)%
(37.0
)%
(42.4
)%
5.4
%
Tables above include Ortho revenues as if the acquisition had
occurred on January 2, 2022.
(a)
The term “constant currency” means we have
translated local currency revenues for all reporting periods to
U.S. dollars using currency exchange rates held constant for each
period. This additional non-GAAP financial information is not meant
to be considered in isolation from or as substitute for financial
information prepared in accordance with GAAP.
(b)
The six months ended July 2, 2023 includes
an approximate $19 million settlement award from a third party
related to one of the Company’s collaboration agreements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230808273784/en/
Investor Contact: Bryan Brokmeier, CFA
IR@QuidelOrtho.com
Media Contact: media@QuidelOrtho.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Apr 2024 to May 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From May 2023 to May 2024